Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:


    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433
    ir@vantiatherapeutics.com         +44(0)7515-397176


    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk / mark.swallow@citigatedr.co.uk /
    helena.galilee@citigatedr.c
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... consulting firm in the life sciences industry, hired ... Blewitt leads the Cloud Compliance Services and Solutions ... companies utilize cloud based applications while maintaining compliance with ... years, Blewitt has been an accomplished life sciences regulatory ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biologics and Biosimilars Industry Report ... The Global Biologics and Biosimilars Industry ... on the current state of the biologics and ... basic overview of the industry including definitions, classifications, ...
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix ... it has completed a collaborative research program ... analytics.  Using Fast Collective Evolution Technology (FACET), ... including all measurements obtained from each of ... Phase 2 clinical trials ASSERT, SUSTAIN and ...
Breaking Biology Technology:USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Global Biologics and Biosimilars Industry Report 2015-2020 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... Agilent Technologies has announced a new network switch ... gigabit per second, using designs bought from a Wisconsin ... based in Eau Claire, designs application-specific integrated circuits and ... implementation of System Packet Interface Level 4 Phase 2, ...
... When Suzanne DeCann visits the University of Wisconsin-Eau ... will be to pick up her newly earned Master of ... be among the first 11 UW-Eau Claire students to earn ... for commencement, shell get her first real look at the ...
... Racine, Wis. Modine Manufacturing Company announced ... at the 19th Annual Agricultural Machinery Conference in Cedar ... conditioning system that does not release dangerous hydrofluorocarbon emissions, ... efficient, all while taking up the same amount of ...
Cached Biology Technology:Agilent's new network chip was designed in Wisconsin 2UW-Eau Claire graduates first online MBAs 2UW-Eau Claire graduates first online MBAs 3
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biometrics ... their offering. The market for biometric ... CAGR of around 14% till 2020 ... will be increasing security needs, government projects and ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... from algae, rosemary and monk fruit could soon replace ... 1, BHT and aspartame that label-conscious grocery shoppers are ... colors, sweeteners and preservatives to naturally derived ones, and ... Chemical & Engineering News , the weekly newsmagazine of ...
... from the Monell Center have used analytical organic chemistry ... human earwax. Further, they found that the amounts of ... and Caucasians. The findings suggest that human earwax, an ... of personal information. "Our previous research has ...
... years with the current poaching rates. The loss of this megaherbivore ... effects on the ecosystems they now live in. The ... drivers of ecosystem functioning because theyre not controlled by predation. ... in Journal of Ecology , highlights the role of the ...
Cached Biology News:Earwax: A new frontier of human odor information 2Poaching threatens savannah ecosystems 2
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
... Life Sciences provides cost effective cell culture ... or monoclonal antibodies. Quality at a reasonable ... you require research or commercial product, we ... methods such as roller bottles, hollow fiber, ...
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
Biology Products: